HemoPill Acute ® in Suspected Nonvariceal Upper Gastrointestinal Bleeding

Last updated: July 8, 2024
Sponsor: Wuerzburg University Hospital
Overall Status: Completed

Phase

N/A

Condition

Hemorrhage

Ulcers

Gastric Ulcers

Treatment

HemoPill Acute ®

Clinical Study ID

NCT04472364
Brand_HemoPill_07_07_2020
U1111-1254-9251
  • Ages > 18
  • All Genders

Study Summary

The study examines, whether the use of the HemoPill Acute ® capsule in case of suspected nonvariceal upper gastrointestinal bleeding can identify cases in which endoscopy can be delayed to 48-96 hours without risk to the patient.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Emergency presentation with clinical suspicion of non-variceal upper GI bleeding (e.g. haematin vomiting, melena, etc.)

  • hemodynamic stable patient (heart rate <100 / min, Blood pressure sys ≥ 100mmHg)

  • Emergency endoscopy indicated (modified Glasgow-Blatchford-Score ≥ 2 points)

  • Administration of proton pump inhibitors possible (no allergy known)

  • Good communication (without translator) with the study doctor and fulfill allrequirements of the study

  • Written consent after detailed information about the study

Exclusion

Exclusion Criteria:

  • Hemodynamically unstable patients (HF> 100 / min, RR <100mmHg despite fluidadministration) with indication for endoscopy within 12 hours

  • Indication for endoscopy within 12 hours recommended by endoscopy call service

  • Clinical suspicion of variceal bleeding of the upper GI tract (risk factorsaccording to german guidelines: cirrhosis of the liver, splanchnic thrombosis,thrombocytopenia, known increased liver / spleen stiffness, known esophagealvarices)

  • Clinical suspicion of lower GI bleeding (e.g. hematochezia)

  • Vomiting blood (hematemesis observed by the emergency doctor or in the clinic)

  • Patients with inflammatory bowel disease (Crohn's disease or ulcerative colitis)

  • Severe acute and chronic organ diseases that need treatment (e.g. kidney replacementtreatment) (ASA ≥4)

  • Changed anatomy of the upper GI tract (e.g. gastric resection)

  • Known or suspected gastrointestinal obstructions, strictures, fistulas or knowndiverticula

  • Dysphagia or other swallowing disorders

  • Awareness restrictions that make it impossible to swallow the HemoPill Acute ®capsule on your own

  • Patients with pacemakers, defibrillators, or other implantable electromedicaldevices

  • Known allergy to parylene (capsule surface)

  • Soon MRI scan planned

  • Pregnancy or breastfeeding

  • Mental impairment that limits the ability to meet all study requirements.

Study Design

Total Participants: 73
Treatment Group(s): 1
Primary Treatment: HemoPill Acute ®
Phase:
Study Start date:
October 08, 2020
Estimated Completion Date:
April 08, 2024

Study Description

Despite a variety of scoring systems (Glasgow-Blatchford-Score, etc.) timing of endoscopy in case of suspecting nonvariceal bleeding in the upper gastrointestinal tract is still challenging.

While very early endoscopy (within 12 hours) is required in some cases, European Society of Gastrointestinal Endoscopy (ESGE) - guidelines recommend performing emergency endoscopy within 24 hours in other cases. However, a recent study (Siau et al. 2019) showed that even this time window is only kept in 59% of cases. Therefore this study examines, whether the use of the HemoPill Acute ® capsule in case of suspected nonvariceal upper gastrointestinal bleeding, can identify cases in which endoscopy can be delayed to 48-96 hours without risk to the patient.

In this study, after the routine administration of a proton pump inhibitor, hemodynamically stable emergency patients suspected of having non-variceal bleeding in the upper gastrointestinal tract receive a novel blood detection capsule (HemoPill Acute ®) for swallowing, whose result is available after 2 hours.

In case of blood detection in the upper gi-tract (capsule positive), the endoscopy will be performed within 12 hours.

If no blood is found in the upper GI tract (capsule negative), endoscopy will be performed after 48 to 96 hours, with the patient being monitored in hospital until then. In these cases, if clinical bleeding occurs before the planned endoscopy, the patient will receive an unscheduled emergency endoscopy.

Further treatment is carried out according to current clinical standards. 30 days after discharge, the patients will be asked by telephone about their further clinical course and possible complications.

The study is planned to recruit 72 participants over 48 months in several centers. If this procedure is found to be safe, the HemoPill Acute ® capsule can be used to reduce the number of emergency endoscopies.

Connect with a study center

  • Klinikum Friedrichshain

    Berlin, 10249
    Germany

    Site Not Available

  • Universitästklinik Freiburg

    Freiburg, 79106
    Germany

    Site Not Available

  • Sana Klinikum Offenbach GmbH

    Offenbach am Main, 63069
    Germany

    Site Not Available

  • Robert-Bosch-Krankenhaus

    Stuttgart, 70376
    Germany

    Site Not Available

  • Universitätsklinik Würzburg

    Würzburg, 97080
    Germany

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.